Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Compliance
Proportion of patients that receive radiotherapy in accordance to prescribed dose and treatment time
End of radiotherapy (approximately 5.5 weeks after start of radiotherapy)
Yes
Jens Overgaard, DrMSc
Principal Investigator
Danish Head and Neck Cancer Group
Denmark: Ethics Committee
DAHANCA 28A
NCT01733823
January 2013
March 2018
Name | Location |
---|